TEL AVIV, Israel, May 8, 2014 (GLOBE NEWSWIRE) -- Alcobra Ltd. (Nasdaq:ADHD), an emerging biopharmaceutical company focused on the development of new medications to help patients with cognitive disorders, including Attention Deficit Hyperactivity Disorder (ADHD) and Fragile X Syndrome, today announced that Dr. Yaron Daniely, President and Chief Executive Officer of Alcobra, will provide a corporate overview at two Israeli conferences in May, 2014.
|
Oppenheimer 15th Annual Israeli Investor Conference |
|
Date: |
Sunday, May 11, 2014 |
|
Time: |
7:10am Eastern/1:10pm GMT +2 |
|
Location: |
David Intercontinental Hotel in Tel-Aviv |
|
|
|
|
MIXiii/BioMed Israel Innovation Conference |
|
Date: |
Wednesday, May 21, 2014 |
|
Panel Title: |
"Riding the IPO Wave" |
|
Time: |
9am Eastern/3pm GMT +2 |
|
Company Presentation |
11am Eastern/5pm GMT +2 |
|
Location: |
Tel-Aviv Fairgrounds |
About Alcobra Ltd.
Alcobra Ltd. is an emerging biopharmaceutical company primarily focused on the development and commercialization of a proprietary drug candidate, MDX (Metadoxine Extended Release (MG01CI)), to treat cognitive dysfunctions including Attention Deficit Hyperactivity Disorder (ADHD) and Fragile X Syndrome. MDX has completed Phase II studies to treat Attention Deficit Hyperactivity Disorder, and is enrolling patients in a Phase III study for this indication in adults. The company was founded in 2008 and is headquartered in Tel Aviv, Israel. For more information please visit the Company's website, www.alcobra-pharma.com, the content of which is not incorporated herein by reference.
CONTACT: U.S. Investor Contacts:
LifeSci Advisors, LLC
Michael Rice
646-597-6979
mrice@lifesciadvisors.com
Israel Investor Contact:
Alcobra Investor Relations
Debbie Kaye
+972-72 2204661
debbie@alcobra-pharma.com
